Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I

Hoffmann, Ursula ; Espeter, Florian ; Weiß, Christel ; Ahmad-Nejad, Parviz ; Lang, Siegfried ; Brückmann, Martina ; Akin, Ibrahim ; Neumaier, Michael ; Borggrefe, Martin ; Behnes, Michael

In: BMC Cardiovascular Disorders, 15 (2015), Nr. 50. pp. 1-12. ISSN 1471-2261

[img]
Preview
PDF, English
Download (2MB) | Lizenz: Creative Commons LizenzvertragIschemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I by Hoffmann, Ursula ; Espeter, Florian ; Weiß, Christel ; Ahmad-Nejad, Parviz ; Lang, Siegfried ; Brückmann, Martina ; Akin, Ibrahim ; Neumaier, Michael ; Borggrefe, Martin ; Behnes, Michael underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: To evaluate diagnostic and long-term prognostic values of hFABP compared to NT-proBNP and troponin I (TnI) in patients presenting to the emergency department (ED) suspected of acute heart failure (AHF). Methods: 401 patients with acute dyspnea or peripheral edema, 122 suffering from AHF, were prospectively enrolled and followed up to 5 years. hFABP combined with NT-proBNP versus NT-proBNP alone was tested for AHF diagnosis. Prognostic value of hFABP versus TnI was evaluated in models predicting all-cause mortality (ACM) and AHF related rehospitalization (AHF-RH) at 1 and 5 years, including 11 conventional risk factors plus NT-proBNP. Results: Additional hFABP measurements improved diagnostic specificity and positive predictive value (PPV) of sole NT-proBNP testing at the cutoff <300 ng/l to “rule out” AHF. Highest hFABP levels (4th quartile) were associated with increased ACM (hazard ratios (HR): 2.1–2.5; p = 0.04) and AHF-RH risk at 5 years (HR 2.8–8.3, p = 0.001). ACM was better characterized in prognostic models including TnI, whereas AHF-RH was better characterized in prognostic models including hFABP. Cox analyses revealed a 2 % increase of ACM risk and 3–7 % increase of AHF-RH risk at 5 years by each unit increase of hFABP of 10 ng/ml. Conclusions: Combining hFABP plus NT-proBNP (<300 ng/l) only improves diagnostic specificity and PPV to rule out AHF. hFABP may improve prognosis for long-term AHF-RH, whereas TnI may improve prognosis for ACM. Trial registration: ClinicalTrials.gov identifier: NCT00143793 .

Item Type: Article
Journal or Publication Title: BMC Cardiovascular Disorders
Volume: 15
Number: 50
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 09 Dec 2015 08:56
Date: 2015
ISSN: 1471-2261
Page Range: pp. 1-12
Faculties / Institutes: Medizinische Fakultät Mannheim > Institut für Klinische Chemie
Medizinische Fakultät Mannheim > Medizinische Klinik - Lehrstuhl für Innere Medizin I
Medizinische Fakultät Mannheim > Medizinische Statistik, Biomathematik und Informationsverarbeitung
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative